The breakthrough, detailed in a prominent study published in the scientific journal Cell, addresses several long-standing manufacturing and physiological bottlenecks that have historically limited the efficacy of immune-based cancer treatments. In preclinical experiments involving mice, these engineered cells successfully integrated into the bone marrow, continuously produced fresh waves of therapeutic immune cells, and effectively slowed the progression of both aggressive blood cancers and stubborn solid tumors.
Led by a team at the USC Stem Cell initiative, the researchers concentrated their efforts on a specific population of immature blood-forming cells known as granulocyte-monocyte progenitors, or GMPs. In a typical biological system, these progenitor cells serve as precursors that naturally develop into macrophages and other protective white blood cells designed to combat infections and regulate immune reactions.
However, the USC investigators discovered that GMPs could be continuously cultivated in a laboratory environment under carefully calibrated conditions while still retaining their foundational ability to mature into functional immune defenders. Furthermore, these cells proved highly receptive to genetic modification, allowing scientists to program them to target specific cancer markers and amplify broader immunological responses.
"The study establishes a scalable and engineerable GMP platform for cellular immunotherapy and introduces concepts that we believe could have broad implications for both cancer immunotherapy and stem cell biology," said the paper’s corresponding author, Qi-Long Ying, MD, PhD, a professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC.
A Surprising Discovery in Immune Cell Precursors
Beyond its direct implications for oncology, the discovery challenges conventional scientific wisdom regarding how blood and immune cells develop and renew themselves within the human body.
In mainstream stem cell biology, the capacity for long-term self-renewal—the ability to divide repeatedly while retaining original properties—has traditionally been attributed almost exclusively to hematopoietic stem cells. These master stem cells reside in the bone marrow and give rise to every major category of blood and immune cell.
Progenitor cells, by contrast, occupy a later stage in cellular development. Because they are already committed to producing a more restricted range of downstream cell types, they are generally believed to possess a severely limited capacity for sustained self-renewal.
The USC research team demonstrated that, under precise laboratory conditions, GMPs can defy this conventional rule. Instead of rapidly maturing and losing their proliferative capacity, the progenitor populations continued to multiply exponentially while preserving their core identity and their unique potential to generate functional immune cells.
"The prevailing view has been that long-term self-renewal in the blood system is primarily a property of the hematopoietic stem cells that can generate any type of blood or immune cell," Ying explained. "We found that, under the right conditions, GMPs can also self-renew, dividing extensively while keeping their identity and ability to produce functional immune cells. That gives us a scalable starting point for engineering cell therapies for cancer, infectious disease and potentially many other conditions."
This revelation provides a reliable foundation for manufacturing the vast quantities of engineered cells required for modern immunotherapies, bypassing the scarcity issues that often hamper traditional treatments.
Why Macrophages Stand Out as Potential Weapons Against Cancer
To understand the significance of targeting GMPs, scientists must look closely at macrophages, which are among the most versatile and powerful agents in the human immune system. Derived from Greek roots meaning "big eaters," macrophages earn their name through phagocytosis—the physical process of surrounding, engulfing, and destroying bacteria, cellular debris, and foreign invaders.
Beyond direct elimination, macrophages act as master coordinators within the immune network, releasing signaling molecules that direct the behavior of neighboring cells. Certain specialized macrophages are capable of migrating directly into tumor microenvironments to attack malignant cells, making them highly attractive candidates for novel cancer therapies.
This migratory capability is particularly valuable when confronting solid tumors, which form dense masses in organs and tissues. While existing cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapies, have achieved remarkable success against liquid tumors like leukemias and lymphomas, treating solid tumors has remained a formidable hurdle. Macrophages offer a promising alternative because they naturally infiltrate tissues and can penetrate the dense architecture of solid masses.
Yet, harnessing mature macrophages for clinical applications has encountered significant biological and logistical roadblocks. Once macrophages reach full maturity, they resist large-scale multiplication outside the body, prove difficult to modify genetically, and frequently suffer structural damage during standard freezing and storage procedures.
Even when successfully administered to a patient, mature macrophages often fail to distribute evenly throughout the body, tending instead to accumulate prematurely in filtering organs like the lungs and liver. Coupled with a relatively rapid natural clearance rate, these limitations restrict how long a macrophage-based therapy can remain active and effective. By shifting their focus upstream to cellular precursors, the USC researchers engineered a workaround to these persistent obstacles.
Creating a Renewable Supply of Cancer-Fighting Immune Cells
Rather than attempting to cultivate and modify billions of fragile, mature macrophages, first author Shi Yue, MD, working in Ying’s laboratory alongside collaborative colleagues, concentrated entirely on GMPs.
The research team formulated a precisely defined chemical cocktail that allowed isolated GMPs to survive, proliferate, and maintain their stem-like properties over extended periods in vitro. This biochemical mixture successfully prevented the progenitors from prematurely differentiating into mature immune cells, thereby preserving a stable, renewable reservoir of precursor cells.
Even after undergoing extensive expansion in the laboratory, the GMPs maintained their defining molecular signatures. More importantly, when exposed to the appropriate biological cues, they retained the full capacity to differentiate into functional macrophages and related immune defenders.
This technological advance makes it feasible to manufacture large batches of engineered cells from a continually expanding master supply, eliminating the need to repeatedly harvest primary cells from patients for personalized preparations.
To validate the reproducibility and robustness of the technique, the USC team partnered with researchers in the laboratory of Ravi Majeti, MD, PhD, at Stanford University. The independent group successfully maintained and genetically engineered GMPs using similar parameters, providing external verification that supports the method’s potential translation into clinical settings.
"This method for the expansion and engineering of GMPs opens the door to numerous translational applications, much like T cell expansion and engineering," noted Majeti, who serves as Director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. "We have already demonstrated engineering of these cells to drive multiple potent functions, and there is a lot more to be explored."
Engineering Immune Cells to Recognize and Attack Tumors
With a scalable system for expanding progenitors established, the team investigated whether these cells could be programmed to actively seek out and destroy cancer cells.
The researchers introduced genetic instructions into the GMPs to express a chimeric antigen receptor, commonly known as a CAR. This synthetic receptor acts as a molecular homing device, allowing the resulting immune cells to pinpoint specific protein markers expressed on the surfaces of tumor cells and direct their destructive energy accordingly.
While CAR technology is a cornerstone of modern T-cell immunotherapy, applying it to GMPs opens up new possibilities for generating engineered macrophages and allied immune cells. To maximize this effect, the scientists equipped a subset of the progenitor cells with an additional immune-activating signal designed to recruit and stimulate nearby endogenous immune cells, including T cells, thereby mounting a coordinated multi-pronged assault on the cancer.
An added benefit of this secondary signal was its consistent performance even when the genetic markers of the donor cells did not precisely match those of the recipient. This finding hints at the future possibility of developing standardized, "off-the-shelf" immunotherapies manufactured in advance from healthy donor tissue, contrasting sharply with current personalized therapies that require separate, time-consuming preparation for each individual patient.
Engineered Cells Slow Cancer Progression in Mice
Following successful expansion and genetic modification of both murine and human GMPs, the research team tested the therapeutic efficacy of the engineered cells in living animal models.
When introduced into mice, the progenitor cells homed in on the bone marrow and other primary hematopoietic niches. These natural environments provided the ideal biological conditions for the GMPs to continuously generate fresh batches of engineered macrophages and related immune defenders from within the host organism.
This internal replenishment strategy addresses the rapid clearance issue that has historically limited the lifespan and effectiveness of traditional macrophage therapies evaluated in clinical trials. By serving as an ongoing factory for new immune cells, the progenitors maintained a sustained therapeutic presence.
In rigorous evaluations involving murine models of both blood cancers and solid tumors, GMPs outfitted with CAR receptors noticeably slowed disease progression across both categories. Therapeutic outcomes were even more pronounced when the progenitor cells carried both the CAR construct and the supplemental immune-activating signal, demonstrating an enhanced capacity to drive a potent, broad-spectrum antitumor response.
While these preclinical results offer significant encouragement, researchers emphasize that further investigation remains necessary to determine whether engineered GMPs can be deployed safely and effectively in humans, particularly regarding their long-term persistence and behavior within the body.
Potential Applications Beyond Cancer Treatment
Beyond oncology, the research team explored whether their expandable progenitor platform could address other pathologies rooted in immune system dysfunction.
In a separate set of experiments involving mice, the scientists investigated chronic granulomatous disease, a severe inherited disorder that impairs the ability of specific immune cells to neutralize harmful microbes. Patients afflicted with this condition suffer from chronic vulnerability to recurrent, difficult-to-treat bacterial and fungal infections because their immune cells fail to eradicate certain pathogens.
When the researchers administered engineered GMPs to mice exhibiting the disorder, the transplanted cells successfully restored the animals’ inherent capacity to combat bacterial infections.
This outcome suggests that renewable, genetically engineered immune cell progenitors could eventually form the basis of advanced treatments for inherited immunodeficiencies and refractory infectious diseases, expanding the footprint of cellular medicine well beyond cancer care.
Ultimately, the findings suggest that the developmental stage chosen for cellular engineering may be just as critical as the genetic modifications themselves. By modifying cells upstream before they reach terminal maturity, scientists may unlock a new generation of immunotherapies that are simpler to manufacture, more versatile in their distribution, and capable of maintaining a self-sustaining defense within the patient.
"Our study suggests that the future of immunotherapy may depend not only on designing better CAR receptors, but also on choosing the right developmental stage of the cell," Ying concluded.
